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Abstract Isolated Langerhans cell histiocytosis (LCH) of
the female genital tract is very rare. A review of the
literature revealed that only 15 cases of primary vulvar
LCH have previously been published in the English
literature. We describe an additional case of confined
vulvar LCH. A 49-year-old woman presented with an
ulcerous lesion that turned out to be LCH confined to the
vulva only. After surgical excision, four recurrences
followed, which were treated again by surgery. After the
fourth recurrence, adjuvant radiotherapy was applied. When
the fifth recurrence occurred, only surgical excision was
performed, and the patient has now been disease-free for
51 months. There are no standard treatment options for this
rare disease. The most effective treatment options still
remain elusive. In our case in the end surgery proved to be
effective.
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Introduction
Langerhans cell histiocytosis (LCH), also known as
histiocytosis X, is a rare disorder of histiocyte proliferation
with histiocytes which are functionally defective in their
antigen-presenting ability. The clinical picture varies great-
ly, ranging from mild to life-threatening. Most often the
disease affects children, and when it occurs in older
patients, groin involvement is quite common [1]. Genital
LCH as the only manifestation of this disease is very
unusual. Initially, Lane and Smith reported LCH in a 6-
year-old child in 1939 [2]. We describe a case of primary
vulvar LCH and review the current literature of this
diagnostically and therapeutically challenging disease.
Case report
A 49-year-old Caucasian woman, gravida 2, para 2,
attended colposcopy clinic for vulvar pruritus. A physical
examination revealed a nodular lesion of 5 mm on the left
vulva (Fig. 1). Regional lymph nodes were not enlarged.
The lesion was biopsied and histological findings revealed
histiocytic proliferation including cells with broad cyto-
plasm and a kidney-shaped nucleus as well as clusters of
eosinophils (Fig. 2). Immunohistochemical stains using
antibodies against CD1a and S-100 protein were positive in
histiocytic cells (Fig. 3). These results were consistent with
the diagnosis of LCH.
Clinical staging including chest X-ray, bone scan and
computed tomography of the thorax, abdomen and pelvis
did not reveal any evidence of disease beyond the vulva.
According to these findings, the patient was diagnosed with
LCH affecting the vulva only. A complete surgical excision
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was performed; the margins were free of disease with a
safety margin of more than 10 mm.
Three months later a similar lesion of the same size was
excised from the right vulva and histopathological exami-
nation confirmed recurrent LCH with margins free of
disease. Only 5 weeks later, two ulcerated lesions (both
2 mm in size) appeared on the left vulva. It proved to be
recurrent LCH that was again surgically excised with
margins free of disease.
During the following 10 weeks, the patient had two
consecutive local recurrences, both on the left vulva, 2 mm
in size, that were surgically removed. Since prior treatments
had been unsuccessful we decided to take a more
aggressive approach and started adjuvant radiotherapy with
34 Gray that was locally applied on the right and left vulva.
The patient did not tolerate it well complaining of
dysaesthesia and pruritus but the ulcers disappeared after
radiotherapy.
However, 14 months later, a vulvar LCH lesion was
surgically treated again and since then the patient has been
without further recurrences for the past 51 months.
Discussion
LCH is a very rare disease, which was initially categorized
into the clinical subtypes of eosinophilic granuloma, Hand-
Schüller-Christian, or Letteres-Siwe disease, depending on
the site and degree of severity [3]. Later, these were found
to be different manifestations of a single disease named
histiocytosis X [4]. Recently this classification has changed
to LCH, in recognition of the primary cell involved.
The pathogenesis of most histiocytoses remains unclear.
A possible cytokine-related pathway [5] and a potential role
of granulocyte-macrophage-colony stimulating factor (GM-
CSF) [6] have been suggested.
There are four distinct patterns of LCH involvement in the
female genital tract: (1) pure genital LCH, in which the disease
is limited to the genital tract only, (2) genital tract LCH with
subsequent multiorgan involvement, (3) oral or cutaneous
LCH with subsequent genital and multiorgan involvement,
and (4) diabetes insipidus with organ involvement [7].
It is unclear why some patients are affected at the
mucosa or skin only while others present with a widespread
disease. There is no correlation between histological
findings and the outcome of the genital lesions. Complete
regression, partial improvement, persistent lesions and
recurrences were found in all the cases described so far.
Genital LCH can be the first presentation of systemic
disease as described by Padula et al. [8]. According to the
literature, 33% of isolated vulvar LCH subsequently
disseminated [7].
Fig. 3 Primarily membraneous staining of histiocytes with CD1a
monoclonal antibody
Fig. 2 Langerhans cells are histiocytes with broad cytoplasm and a
kidney-shaped nucleus along with clusters of eosinophils (H&E, 100×)
Fig. 1 Uncharacteristic presentation of the vulvar LCH lesion
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Localized lesions of LCH are very unusual and should
be differentiated by a tissue biopsy from other dermatologic
disorders such as diaper rash, seborrhoea dermatitis,
eczema, genital tuberculosis and sexually transmitted
diseases (syphilis, herpes and granuloma inguinale). Sever-
al neoplastic processes can also resemble LCH, including
squamous cell carcinoma, malignant melanoma, sarcoma
and Paget’s disease of the vulva.
As in our patient, the macroscopic and colposcopic
aspect of the lesions were unspecific as were the clinical
symptoms.
The diagnosis of LCH is performed by tissue biopsy
only. The routine evaluation should include serum electro-
lytes and chest X-ray, CT of the abdomen and pelvis, and a
bone scan.
Since the very first case of primary vulvar LCH
described in 1939 by Lane et al. [2], a total of 15 cases
have been published in the English literature. Table 1
summarizes the cases, clinical presentations and treatment
options of all cases. Because of the paucity of data, there is
no standard recommendation for the management of vulvar
LCH. The treatment is not well defined and is highly
individualized. One difficulty is the unpredictability of the
course of LCH.
Treatment regimens have primarily included surgery,
radiotherapy and chemotherapy. Other forms of treatment
have also been used including topical corticosteroids,
topical nitrogenated mustard, thalidomide, or combined
therapy with varying results. Axiotis et al. [7] suggest
treating genital lesions initially by complete excision, but
fifty percent of the patients with genital LCH relapsed after
surgery [19]. This is what happened to our patient, too.
After three recurrences that were all surgically removed, we
performed a local radiotherapy to avoid systemic side
effects but still to allow for a more aggressive approach. A
combined forum of gynaecologists, oncologists, patholo-
gists and radio-oncologists discussed and decided on the
treatment options.
Yet 14 months after radiotherapy another recurrence
occurred and surgery was again performed. Since then the
patient has been disease-free for the past 51 months. The
patient does not have any complaints and is very satisfied.
Apart from the case described by Axiotis et al. [7], this is
the longest follow-up reported in literature.
Determining the success of therapy is restricted by the
limited follow-up information in the majority of studies
previously reported. Most of the patients experienced
recurrences after their initial treatment, and all these
recurrences were vulval.
We performed wide surgical excision and the margins
were always free of pathologic cells. Despite the patient
having three recurrences, we consider radical vulvectomy
as unnecessary in LCH as it is a very radical surgical
approach and there is no support in the published data that
the outcome is improved after radical vulvectomy.
The superior outcomewith the use of thalidomide [15] may
be explained by its action on tumour necrosis factor alpha.
Chemotherapy for multisystem disease is beneficial [20],
but there are few data referring to the use of chemotherapy
for very localized disease. Systemic treatment with vincris-
tine did not clear up the lesions of the patient described by
Solano et al. [13], and after a surgical excision was
performed, the patient remained cured. The patient that
was treated according to the LCH II protocol with
vinblastine and prednisone by Mottl et al. [21] relapsed as
well after 8 months and received a second-line treatment
Table 1 Cases reported in literature of primary Langerhans cell histiocytosis of the vulva
Report Age Clinical presentation Excision Radio-therapy Chemotherapy Others Response Outcome
(months)
Weidmann [9] Unknown Ulcers + − − − PR LTF
Rose [10] 50 Ulcers − + − − PR LTF
Axiotis et al. [7] 85 Ulcers − − − Corticosteroid No response LTF
Voelklein et al. [11] 36 Ulcers − + − − CR NEOD (12)
Savell et al. [12] 76 Erythematous plaques − − + − CR NEOD (8)
Solano et al. [13] 40 Erythematous plaques + − + − CR NEOD (18)
Pather et al. [14] Unknown Ulcers + − − − CR NEOD (24)
Santillan et al. [15] 33 Nodular lesion + + − Thalidomide CR NEOD (5)
Dietrich et al. [16] 41 Nodular lesion + + + − CR LTF
29 Nodular lesion + + − Corticosteroid PR LTF
Padula et al. [8] 31 Ulcers + + − Thalidomide CR NEOD (36)
52 Ulcers − + − − CR NEOD
Venizelos et al. [17] 64 Ulcers + + − − CR NEOD (22)
Ishigaki et al. [18] 65 Ulcers + − − − CR NEOD (12)
Mlyncek et al. [4] 63 Ulcus + − − − CR NEOD (12)
Present report 49 Nodular lesion and ulcers + + − − CR NEOD (41)
CR Complete response, PR partial response, LTF lost to follow-up, NEOD no evidence of disease
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with 2-chlorodeoxyadenosine. Eighteen months later she
still has no sign of recurrence. According to Rodriguez-
Galindo [22], 2-chlorodeoxyadenosine is a good option for
the treatment of recurrent LCH.
The use of radiotherapy is also very controversial. A
retrospective study about the use of radiotherapy in
multisystem disease describes successful applications as
single treatments or in combination with other therapies
[23], but again there are few data about its use in local
LCH. The patient described by Santillan et al. [15] relapsed
after radiotherapy, as did our patient.
Conclusion
LCH should be considered when diagnosing and treating
vulvar lesions. Isolated vulvar LCH has the potential for
aggressive clinical behaviour either as local recurrence or as
disseminated disease. The absence of controlled studies and
the lack of standard diagnostic evaluation criteria have
impeded therapeutic progress. There are no standard treat-
ments, but we consider surgery as the best option with the
fewest side effects and recommend it as first- and second-
line treatment in patients with vulvar LCH.
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